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Abstract
Purpose Prostate-specific membrane antigen (PSMA)-
targeting radioligand therapy (RLT) was introduced in 2011.
The first report described the antitumor and side effects of a
single dose. The aim of this analysis was to evaluate toxicity
and antitumor activity after single and repetitive therapies.
Methods Thirty-four men with metastatic castration-resistant
prostate cancer received PSMA-RLT with 131I-MIP-1095.
Twenty-three patients received a second, and three patients a
third dose, timed at PSA progression after an initial response
to the preceding therapy. The applied doses were separated in
three groups: <3.5, 3.5–5.0 and >5.0 GBq. Antitumor and
side-effects were analyzed by blood samples and other clinical
data. Follow-up was conducted for up to 5 years.
Results The best therapeutic effect was achieved by the first
therapy. A PSA decline of ≥50%was achieved in 70.6% of the
patients. The second and third therapies were significantly less
effective. There was neither an association between the
applied activity and PSA response or the time-to-progression.
Hematologic toxicities were less prevalent but presented in a
higher percentage of patients with increasing number of
therapies. After hematologic toxicities, xerostomia was the
second most frequent side effect and presented more often
and with higher intensity after the second or third therapy.
Conclusion The first dose of RLT with 131I-MIP-1095 pre-
sented with low side effects and could significantly reduce
the tumor burden in a majority of patients. The second and
third therapies were less effective and presented with more
frequent and more intense side effects, especially hematologic
toxicities and xerostomia.
Keywords Prostate cancer . PSMA . Prostate-specific
membrane antigen . Endoradiotherapy
Introduction
The clinical translation of 99mTc-, 18F- and 68Ga-labeled
prostate specific membrane antigen (PSMA)-targeting tracers
for single-photon emission tomography (SPECT) or positron
emission tomography (PET) are considered a significant step
forward for the diagnostics of prostate cancer (PCa) [1–5].
The very first small-molecule PSMA ligands that presented
convincing results in men were 123I-MIP-1072 and 123I-MIP-
1095 [6]; which were described in the literature in 2009 [7].
However, these pioneering ligands were under-recognized at
their introduction. One reason might be that the medium-
energy cyclotron-produced 123I is more expensive then com-
pact cyclotron-produced 18F or generator nuclides such as
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99mTc or 68Ga. On-site labeling with radioiodine can also be
more complex than labeling of chelator-containing ligands.
Since internalization occurs after binding of antibodies and
small-molecule ligands to PSMA, these molecules may also
be good candidates for endoradiotherapy [8]. First therapy
was done with the monoclonal antibody J591. In phase 1
and 2 clinical trials, J591 was radiolabeled with 90Y or 177Lu
leading to promising early results [9–11]. However, monoclonal
antibodies are large molecules which show poor permeability in
solid tumors and slow clearance from the circulation. Due to
their specific tumor targeting and faster pharmacokinetics in
comparison to full-length antibodies, small-molecule
PSMA ligands were also considered promising for systemic
radioligand therapy (RLT) of metastatic prostate cancer.
DOTA or DOTAG -chelator-containing ligands can easily be
labeled with a variety of different diagnostic or therapeutic
radionuclides, making them favorable candidates for clinical
application. Finally, such compounds became available in
2013 and first clinical results were now published in 2016
[12–21]. However, the first PSMA RLTs based on a
radioiodine-labeled compound were already conducted
between July 2011 and June 2012 [22]. After PET-based
dosimetry with 124I-MIP-1095, 28 patients received one
single treatment with 131I-MIP-1095 and were followed
until first PSA progression [22]. An additional eight
patients received their first cycle of 131I-MIP-1095 after-
wards, before PSMA RLT was switched to 177Lu-PSMA
ligands.
Here, we report our long-term follow-up of 34 patients with
a special focus on repeated 131I-MIP-1095 therapies, which




Between July 2011 and October 2013, 36 men with pro-
gressive metastatic castration-resistant prostate cancer
(mCRPC) were referred to PSMA RLT after having
received all approved therapies available at that time.
A PSMA-positive tumor phenotype was demonstrated
with 68Ga-PSMA-11 PET/CT. The characteristics of all 36
patients who received at least one therapy with 131I-MIP-
1095 are given in Table 1. Out of these, two patients were
lost for follow-up. Twenty-three of the remaining patients
received a second and three patients received a third
therapy. Overall, 60 treatments were applied in the 34
evaluable patients. The second and third therapeutic ac-
tivity was applied in case of PSA progression following
an initial decline after the first therapy (supplementary
figure 1).
The follow-up until first PSA progression of 28
patients receiving one single therapy has previously been
published [22].
Depending on the efficiency of radiolabeling, patients
received an average radioactivity of 4.2 ± 1.4 GBq (1.9–7.2;
median 3.7) for the first therapy. The activities of the second
and third therapies were also depending on labeling yields.
However, if blood cell count was not completely recovered,
the responsible physician could indicate individual dose
reductions. For the second therapy, we applied 3.2 ±
1.2 GBq (2.0–6.4; median 2.7) and for the third therapy, 2.4
± 1.0 GBq (1.5–3.5; 2.2). In order to evaluate possible asso-
ciation of side effects with therapy doses, the applied doses
were separated in three groups: <3.5 GBq (group 1), 3.5–
5.0 GBq (group 2) and >5.0 GBq (group 3).
On the first (prior to radioactivity administration) and on
the last day of the hospitalization, blood samples were collected
from all patients for the measurement of the following
parameters: hematology, electrolytes, glutamic oxaloacetic
transaminase, glutamate-pyruvate transaminase, gamma-
glutamyl transferase, alkaline phosphatase, bilirubin, urea,
creatinine, glomerular filtration rate, prostate-specific antigen
(PSA), thyroid-stimulating hormone, free triiodothyronine
and free thyroxine.
In order to reduce possible thyroid uptake of free
radioiodine, 60 drops of sodium perchlorate (Irenat®, Bayer,
Berlin, Germany) were given p.o. ca. ½ h prior to therapy and
3 × 20 drops in the next 14 days after therapy administration.
Also, prior to therapy, the patients received 1000–2000 mL of
0.9% NaCl solution over 1 day. The therapy solution
(described below) was administered by intravenous infu-
sion over 20–30 min.
Post administration, patients were treated as in-patients
on the nuclear medicine therapy ward for 5–8 days
according to German radiation protection laws. The vital
parameters as well as side effects or adverse effects were
recorded during the whole hospitalization time. In an at-
tempt to to reduce therapy-induced damage of the salivary
glands, the patients received five times per day lemon
juice and ice packs during the first day to reduce organ
perfusion over the parotids and submandibular glands for
the period of their hospitalization.
Whole-body scintigraphy was acquired at the last day of
the hospitalization. The patients were then followed-up further
for side effects and blood parameters taken every 2 weeks over
a period of 10 weeks (the thyroid parameters were controlled
monthly by blood tests). After the 10th week, the frequency of
the blood analyses was at the discretion of the treating oncol-
ogists. Any further (long-term) available information about
the relevant medical history of the patients was collected until
the death of the patients. At the time this manuscript was
submitted, four patients were still living while all others have
passed away.
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Hematologic toxicitieswere analyzed according to common
terminology criteria (CTC) of the World Health Organization.
Xerostomia grades were as follows: grade 0 (no toxicity),
grade 1 (measurable in sctintigraphy only), grade 2 (noticeable
for patients, but no treatment required), grade 3 (treatment
required), grade 4 (significant impairment) and grade 5 (per-
cutaneous endoscopic gastrostomy required). Dysgeusia, xe-
rophthalmia and fatigue syndrome were recorded as present
or absent, including their duration. Bone pain was recorded as
present or absent including, its change after the therapy.
In case of biochemical relapse of PCa, the patients
were re-evaluated for an additional therapy with 131I-
MIP-1095. Requirements for this additional therapy were
a sufficient bone marrow reserve (leucocytes ≥3000/μl
blood; platelets ≥75,000/μl blood) and a response to the
prior therapy shown by PSA decline and/or morphological
response demonstrated by computed tomography (CT),
magnetic resonance imaging (MRI) or positron emission
Tomography (PET) with 68Ga-PSMA-11.
Radiopharmaceutical
The radioiodinated compound 131I-MIP-1095 was prepared as
described previously [22]. Briefly, 131I-MIP-1095 was prepared
by iododestannylation of the trimethylstannyl precursor (S)-
d i t e r t - b u t y l 2 - ( 3 - ( ( S ) - 1 - t e r t - b u t o x y - 1 - o x o -
6-(3-(4-(trimethylstannyl)phenyl)ureido)-hexane-2-
yl)ureido)pentanedioate, to form (S)-2-(3-((S)-1-carboxy-
5-(3-(4 [131I]iodophenyl)ureido)-pentyl)ureido)pentanedioic
acid. [131I]NaI (approx. 7.4 GBq, GE Healthcare) was reacted
with 100 μL of a 250-μg/mL solution of (S)-di-tert-
b u t y l 2 - ( 3 - ( ( S ) - 1 - t e r t - b u t o x y - 1 - o x o -
6-(3-(4-(trimethylstannyl)phenyl)ureido)hexane-2-
yl)ureido)pentanedioate in ethanol and 50 μL of a freshly pre-
pared solution of 0.15 mL of 30% hydrogen peroxide in
0.85 mL of acetic acid. The reaction mixture was diluted after
5 min with 1.5 mL of water and loaded onto a SOLA cartridge.
The cartridge was washed with 2 mL of water to remove
unreacted radioiodide and inorganic and organic salts and dried
by a stream of nitrogen. The cartridgewas eluted using 500μl of
neat trifluoroacetic acid (TFA) and incubated at room tempera-
ture (RT) for 7min. Upon dilutionwith 5ml of H2O, the product
was loaded onto a Bond Elut cartridge and washed with 5 ml of
20% ethanol in water; the product was eluted using 1 ml of
ethanol, neutralized with phosphate buffer and sterile-filtered.
Statistical analysis
For statistical analysis, SigmaPlot version 12 (Systat Software
Inc., Chicago, IL, USA) was used. Patients were classified into
three groups (as mentioned above) according to the adminis-
tered therapeutic doses. Differences between these three groups
with regard to PSA response, decline of leucocytes, decline of
platelets and time to PSA progression were assessed for statis-
tical significance using Kruskal–Wallis tests. In all cases, a p
value of <0.05 was considered statistically significant.
Results
Therapy efficacy
Figure 1 represents a case of disease progression following
therapy response. The best PSA responses to the RLTs are listed
in Fig. 2. Different levels of PSA response following the first,
second and third therapies are listed in Table 2. With regard to
the whole patient cohort, mean time to PSA progression (TTP)
was 116 ± 141 days (range 18–735; median 75) after the first
therapeutic administration, 60 ± 28 days (range 28–117; medi-
an 50) after the second and 42 days (n = 1) after the third PSMA
RLTwith 131I-MIP-1095. Dose-related PSA response and time
to progression after the endoradiotherapies are listed in Table 3
and Fig. 3.
As visible by the mentioned figure and tables, the second
and third therapies were significantly less effective compared
to the first therapy. There was neither an association between
Table 1 Patients’ characteristics
1st Therapy 2nd Therapy 3rd Therapy
Dose (GBq) 4.2 ± 1.4 (1.9–7.2) 3.2 ± 1.2 (2.0–6.4) 2.4 ± 1.0 (1.5–3.5)
Time to PSA progression (d) 116 ± 141 (18–735) 62 ± 28 (28–117) 42*
PSA baseline (ng/ml) 261 (1.1–2109.0) 212 (0.3–1497.0) 480 (125.0–878.0)
Chemotherapy prior
to PSMA therapy
CRPC Age (mean, range)
14/34 (44%) All patients 68 (49–81)
Types of PCa






* Only one patient presented with PSA decline after the third cycle; all others presented with continuous progressive disease despite RLT
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the applied activity and PSA response (first therapy: p = 0.70;
second therapy: p = 0.74) nor between the applied activity and
the time to progression (first therapy: p = 0.19; second thera-
py: p = 0.61).
Safety and side effects
No acute toxicity or side effects were observed in any patient
during their hospitalization time (5–8 days) except one patient
who reported dysgeusia after the second therapy. The
dysgeusia went on for 2 weeks.
A measurable decline of blood cells within the first
10 weeks after each therapy was observed for leucocytes
and platelets only (Fig. 4). However, according to the WHO
CTC, no clinically relevant hematologic toxicities were ob-
served in the majority of the patients (Table 4). CTC grade 1, 2
and 3 hematologic toxicities were less prevalent but presented
in a higher percentage of patients with increasing number of
therapies (Table 4).
No significant value alterations were observed for glutamic
oxaloacetic transaminase, glutamate-pyruvate transaminase,
gamma-glutamyl transferase, alkaline phosphatase, bilirubin,
urea, creatinine, glomerular filtration rate, thyroid-stimulating
hormone, free triiodothyronine and free thyroxine (data not
shown).
No association was found between the three different dose
groups (<3.5; 3.5–5.0 and >5.0 GBq) and best PSA response,
decline of leucocytes, decline of platelets and time to PSA
progression after the therapies. The p values for the first ther-
apy were as follows: 0.70 for best PSA response; 0.26 for
decline of leucocytes, 1.00 for the decline of platelets and
0.19 for the time to PSA progression. The p values for the
Fig. 2 Best PSA response after the first, second and third therapies with
131I-MIP-1095. As demonstrated by this figure, the second and third
therapies were significantly less effective compared to the first therapy.
There was no association between the applied activity and the PSA
response (first therapy: p = 0.70; second therapy: p = 0.74). Blue bars:
patient group 1 (<3.5 GBq applied activity); black bars: patient group 2
(3.5–5.0 GBq applied activity); red bars: patient group 3 (>5 GBq applied
activity)
Fig. 1 Patient no. 2 received three therapies with 131I-MIP-1095. Staging
before and after each therapy was conducted with PSMA ligand PET/CT
(124I-MIP-1095 and 68Ga-PSMA-11). The first two therapies reduced the
tumor burden. However, the third therapy didn’t show a sufficient effect.
The last two pictures on the right side show the rapid progress between
September and November. The images of the PET scans show the
maximum intensity projections, those of the therapies show the
geometric mean of the gamma-ray co-emission which enables imaging
during therapy
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second therapy were as follows: 0.74 for best PSA response;
0.17 for decline of leucocytes, 0.23 for the decline of platelets
and 0.61 for the time to PSA progression. The statistical anal-
ysis could not be applied in the group with three therapies due
to low number of patients (n = 3).
Xerostomias higher than grade 1 occurred more frequently
in patients with a higher number of therapies (Table 4). The
duration evaluation of this side effect was challenging. Most
patients reported recovery from xerostomia after a few weeks.
The duration appeared to be longer after the second or third
therapy in most cases.
Dysgeusia occurred only in one patient after the second
therapy (Table 4). Xerophthalmia was observed only in one
patient after the second therapy. Fatigue syndromes were rare;
no higher prevalence was observed with therapy numbers.
The first therapy had the strongest effect on bone pain: the
majority of the patients who presented with bone pain reported
a relevant reduction of the pain (reduction of analgesics or
improved well-being) after the therapy. The second and third
therapy led significantly less frequently to pain reduction
(Table 4).
Overall survival
The median overall survival (mOS) of the patients after the
first therapy with 131I-MIP-1095 was 17 months
(Supplementary Table 1). At the submission of this manu-
script, four patients were still alive; all of these four patients
received abiraterone or enzalutamide after biochemical re-
lapse following 131I-MIP-1095 therapies. The time to PSA
progression of these patients was for patient 3: 64 days after
the first therapy and progressive from the beginning of the
second therapy; for patient 4: 649 days after the first therapy;
for patient 31: 85 days after the first therapy and for patient 33:
735 days after the first therapy.
Discussion
We retrospectively report the long-term follow-up of 34 pa-
tients who received ≥1 treatment with 131I-MIP1095 PSMA
RLT between 2011 and 2013.
Table 3 Dose-related PSA
response and time to progression
following endoradiotherapy with
131I-MIP-1095
Group 1 (<3.5 GBq) Group 2 (3.5–5.0 GBq) Group 3 (>5.0 GBq)
1st Therapy (n = 10) (n = 14) (n = 10)
Best PSA response ≥25% 100% 79% 100%
Best PSA response ≥50% 60% 64% 70%
Best PSA response ≥75% 40% 36% 40%
Any PSA response 100% 86% 100%
TTP (PSA; days)* 63 ± 24 (28–90; 75) 153 ± 210 (18–735; 65) 91 ± 24 (28–91; 56)
2nd Therapy (n = 15) (n = 5) (n = 3)
Best PSA response ≥25% 50% 57% 100%
Best PSA response ≥50% 29% 57% 50%
Best PSA response ≥75% 7% 14% 0%
Any PSA response 57% 71% 100%
TTP (PSA; days)* 53 ± 24 (28–91; 50) 74 ± 41 (29–117; 74) 57 ± 24 (28–91; 56)
3rd Therapy (n = 2) (n = 1)
Best PSA response ≥25% 0% 100% –
Best PSA response ≥50% 0% 0% –
Best PSA response ≥75% 0% 0% –
Any PSA response 0% 100% –
TTP (PSA; days)* 42∼ – –
* TTP: time to progression of PSA in days. ∼Only one patient presented with PSA decline after the third cycle; all
others presented with continuous progressive disease despite RLT
Table 2 PSA responses to the
first, second and third therapies
with 131I-MIP-1095
Any PSA response ≥25% PSA decline ≥50% PSA decline ≥75% PSA decline
1st therapy n = 32 (94.1%) n = 29 (85.3%) n = 24 (70.6%) n = 13 (38.2%)
2nd therapy n = 15 (65.2%) n = 13 (56.5%) n = 7 (30.4%) n = 2 (8.7%)
3rd therapy n = 1 (33.3%) n = 0 n = 0 n = 0
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Until now—and regardless of the used radiopharmaceuti-
cal—no prospective clinical trials about PSMA RLT were
initiated by pharmaceutical companies. Therefore, all experi-
ence with PSMA RLT is based on salvage therapies that were
administered as an Bunproven intervention in clinical
practice^ (Helsinki Declaration). A pre-requisite for this ap-
proach is that patients previously exhausted (or were consid-
ered Bunfit^ to receive) all approved therapies. Thus, in con-
trast to a clinical trial, inclusion criteria are not constant over
time. In regard to CRPC, the spectrum of approved
Fig. 4 Clinically relevant
hematologic toxicity was
observed with regard to
platelets and leucocytes.
W0-W10: average values of the
pretherapeutical state (W0) to
10 weeks after therapy
administration (W10)
Fig. 3 Average time to PSA progression following 1–3 RLTwith 131I-MIP-1095. There was no association between applied radioactivity and the time to
progression (first therapy: p = 0.19; second therapy: p = 0.61)
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pharmaceuticals changed dramatically during the reported in-
clusion period.
In Europe, abiraterone was approved for patients pre-treated
with docetaxel in 09/2011 and before chemotherapy in 01/2013.
Enzalutamide was first approved 06/2013 to be used after doce-
taxel and in 12/2014 to be used before docetaxel. Cabazitaxel is
approved as a second-line chemotherapy only, since 2011. In 12/
2012 223RaCl was approved for a subgroup of patients with
bone-confined tumor spread. Dependent on the actual approved
indication, practical availability and the patient’s appropriateness
to receive chemotherapy, which was classified by the responsi-
ble uro-/oncologist independently from the nuclear medicine
physician, alternative optionswere given priority even if patients
presented with a good response to the previous PSMA RLT.
This explains the low number of 2nd and 3rd therapies, despite
>70% of patients having a decline of >50% in serum PSA and
an mTTP of 116 days after the first treatment.
Nevertheless, despite being heterogeneous, these data are
still of particular interest because they present the only experi-
ence with PSMA RLT in the pre-abiraterone, pre-enzalutamid,
pre-223RaCl era. In contrast, reports in recent publications
about 177Lu-labeled PSMA RLT have been for patients after
secondary hormone manipulation [13, 14, 20, 23–25]. There is
growing experience about cross-resistance between
abiraterone and enzalutamide [26] as both drugs are targeting
the androgen receptor (AR) axis. If it would be possible to keep
these treatment lines apart by interleaving non-AR-targeting
therapies such as PSMA RLT, the interruption of selection
pressure eventually might reverse cross-resistance. One case
report about restored hormone response after 177Lu-PSMA-
617 generates a promising thesis [27]. In our collective, there
are four still-living patients, which were successfully bridged
by 131I-MIP1095 RLTs until novel options became available
and who now present with enduring responses to the
succeeding secondary hormone manipulations.
In contrast to the before-mentioned publications about
PSMA RLT [13, 14, 20, 23–25], in our cohort, the succeeding
application of the radiopharmaceutical was delayed until pro-
gression of disease. One observation is that the mTTP after each
further treatment decreases. Treatment regimens administered in
cycles of fixed intervals shorter than the here-observed mTTP of
75 days (2.5 months) might be one option to prolong
progression-free survival. In 2013, our department switched to
PSMA-RLT intervals of every two months and the mTTP dou-
bled to about 5 months [14] which is also in accordance to the
prolonged PFS reported by other groups [13, 20]. Nevertheless,
Table 4 Side effects and effects on bone pain of endoradiotherapy with 131I-MIP-1095
1st Therapy 2nd Therapy 3rd Therapy
Thrombopenia No relevant toxicity in 28 patients (82.4%) No relevant toxicity in 15 patients (65.2%) No relevant toxicity in 2 patients (66.6%)
(CTC Grade) Grade 1 in 3 patients (8.58%) Grade 1 in 2 patients (8.7%) –
Grade 2 in 1 patients (2.9%) Grade 2 in 3 patients (13.0%) –
Grade 3 in 2 patients (5.9%) Grade 3 in 2 patients (8.7%) –
– – Grade 4 in 1 patient (33.3%)
– Grade 1→Grade 3 in 1 patient (4.3%) –
Leukopenia No relevant toxicity in 20 patients (58.8%) No relevant toxicity in 11 patients (47.8%) No relevant toxicity in 1 patient (33.3%)
Grade 1 in 8 patients (23.5%) Grade 1 in 6 patients (26.0%) Grade 1 in 1 patient (33.3%)
Grade 2 in 5 patients (14.7%) Grade 2 in 4 patients (17.4%) Grade 2 in 1 patient (33.3%)
Grade 3 in 1 patient (2.9%) – –
– Grade 1→ grade 2 in 2 patient (8.7%) –
Xerostonia Grade 0 in 4 patients (11.8%) Grade 0 in 0 patient (0.0%) Grade 0 in 0 patients (0.0%)
Grade 1 in 24 patients (70.6%) Grade 1 in 14 patients (60.9%) Grade 1 in 2 patients (66.6%)
Grade 2 in 6 patients (17.6%) Grade 2 in 6 patients (26.1%) Grade 2 in 0 patients (0.0%)
Grade 3 in 0 patients (0.0%) Grade 3 in 3 patients (13.0%) Grade 3 in 1 patient (33.3%)
Dysgeusia None 1 Patient (4.3%) None
Xerophthalmia None 1 Patient (4.3%) None
Fatigue 2 Patients (5.9%) 2 Patients (8.7%) 1 Patient (33.3%)
Bone pain Pain prior to therapy: 16 patients (47%) Pain prior to therapy: 11 patients (47.8%) Pain prior to therapy: 2 patients (66.6%)
Reduction after therapy: 15 patients
(93.8%)
Reduction after therapy: 3 patients (27.3%) Reduction after therapy: 0 patients (0%)
Uncharged intensity after therapy: 1
patient (6.2%)
Uncharged intensity after therapy: 8 patients
(72.7%)
Uncharged intensity after therapy: 2 patients
(100%)
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it remains unclear whether a prolonged mPFS or mTTP
achieved by intensified treatment regimens will finally also
translate into a longer mOS.
Based on the dosimetry estimates with 124I-MIP1095 PET
and extrapolation to 131I-MIP1095 RLT [22], the mean
absorbed doses to salivary glands are 4.62 Gy/GBq and to
the red marrow 0.31 Gy/GBq. A therapy with 4 GBq 131I-
MIP1095, therefore, corresponds to an 18.5-Gy salivary gland
dose and a 1.2-Gy red marrow dose. A red marrow dose of
2 Gy is considered safe for RLT and, therefore, the here-
reported low number of grade 3 hematological toxicities
(6%) after the first therapy are within the expectations.
Nevertheless, as demonstrated by Fig. 4, a moderate depres-
sion of blood cell count was observed after each cycle with the
nadir around 6 weeks post-therapy. PSMA RLT with the
radiolabeled antibody 177Lu-J591 resulted in comparable red
marrow doses [9] and hematological toxicity as well as the
platelet nadir are also in accordance with our results [28]. In
contrast, with 177Lu-PSMA-617, the red marrow dose is about
0.025–0.03 Gy/GBq [14, 29] and therapy with 6 GBq 177Lu-
PSMA-617 translates into an estimated red marrow dose of
0.15–0.2 Gy. Thus, the even better tolerability of this
radioconjugate regarding hematological toxicity is reasonable.
With 177Lu-PSMA-617, 1.4 Gy/GBq (e.g. 8.4 Gy for 6 GBq)
has been calculated as the salivary gland’s absorbed dose [29].
Thus, it is plausible that we find a higher incidence of moderate
xerostomia with our treatment regimen than it is reported for
177Lu-PSMA RLT [13, 14, 20, 23–25]. However, with 131I-
MIP-1095, we also found a higher rate of responders in regard
to both Bany PSA decline^ (94%) and B>50% PSA decline^
(71%). In the largest report (n = 82) about 177Lu-PSMA-617
administered in fractions of 6 GBq [30], the corresponding re-
sponse rates for Bany PSA decline^ (64%) and B>50% PSA
decline^ (31%) were remarkably lower. As the variability of
absorbed dose to different tumor lesions is high, no reliable
comparison between the two ligands regard to their therapeutic
range is possible. We would emphasize that dose escalation of
177Lu-PSMA-617 will increase both response rate and toxicity.
Alternatively, de-escalation of 131I-MIP-1095 seems also a rea-
sonable concept because there was no relevant difference in
response rate between patients that received <3.5 or >5 GBq
131I-MIP-1095 (Table 3). As stated above, the analysis of this
paper was done during the pre-abiraterone and pre-enzalutamide
era which is in contrast to the newer reports with 177Lu-PSMA-
617. Clinical studies revealed an increase of PSMA expression
in tissue specimens after androgen-deprivation therapy [31, 32].
At present, no data are available concerning a further increase or
a decrease of PSMA expression after abiraterone and/or
enzalutamide. Therefore, application of 131I-MIP-1095 in a sim-
ilar clinical setting may deliver a better data set for comparison.
On the other hand, it is known that the later a therapy line is
applied, the lower the efficacy due to an increase of tumor ag-
gressiveness [33, 34].
One reason that more centers currently rely on 177Lu-
labeled PSMA ligands is the lower co-emission of gamma
radiation. 131I has an 82% abundance probability for high-
energetic (364 keV) γ-radiation and an 89% abundance
probability for β-radiation (606 keV). In contrast, 177Lu
has a γ co-emission of only 11% (210 keV) but a 100%
abundance probability for β-radiation (490 keV).
Depending on radiation protection acts, this can translate
into different needs for isolation. Our patients who were
treated with 131I-MIP-1095 had an average hospitalization
time of 7 days while those treatedwith 177Lu-PSMA-617were
hospitalized for 2 days. A second reason might be the level of
efforts for radiolabeling. Chelator-containing ligands can
be labeled with high and robust labeling yields, the synthesis
of 131I-MIP-1095 on-site were one reason for the high vari-
ance of treatment activity. However, this might easily be over-
come by a routine production by commercial companies.
Conclusion
The first clinical experience with therapeutic small-molecule
PSMA ligands was using 131I-MIP-1095 as a single-cycle ther-
apy. The here-reported experience of repeated applications of
PSMA RLT after the next PSA relapse is still unique. The
deepness of PSA response and duration of tumor control was
most pronounced with the first therapy but repeated treatments
were already facing resistance. Repeated full-dose therapy also
causes more side effects such as hematological toxicity and
xerostomia. This provides a rationale for metronomic or frac-
tionated treatment regimens. The first experiences based on
fractionated therapy with 177Lu-PSMA ligands have recently
been published. However, it has yet to be proven which of
these concepts will be superior with regard to overall survival.
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